A clinical-stage dermatology company focused on identifying, developing, and commercializing topical drug products for the treatment of skin diseasesRead MoreProprietary microencapsulation delivery system with potential to enhance therapeutics and outcomesRead MoreDiversified and innovative clinical-stage dermatological pipelineRead More

TWYNEO® Treatment for
Acne Vulgaris
is now FDA APPROVED

Learn More

EPSOLAY® Treatment for
Inflammatory Lesions of Rosacea
is now FDA APPROVED

Learn More

Novel Delivery Technology Designed to Control Topical Drug Release

Research is currently being conducted using our proprietary silica-based delivery technology, which utilizes a microencapsulation process, to determine if it improves the tolerability of topical dermatological drug products. The topical delivery technology is designed to control the release profile of drug substances.

New Drug Combinations

Research using our proprietary silica-based delivery technology platform is also ongoing to determine if two otherwise incompatible drug substances can be combined in the same formulation.

Our Product Pipeline

Sol-Gel is developing a diverse pipeline of innovative topical skin medications, some based on our propriety silica-based delivery technology.

View Our Pipeline